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Background: Aberrant DNA methylation is a hallmark of many cancers. Classically there are two types of
endometrial cancer, endometrioid adenocarcinoma (EAC), or Type I, and uterine papillary serous carcinoma
(UPSC), or Type II. However, the whole genome DNA methylation changes in these two classical types of
endometrial cancer is still unknown.
Results: Here we described complete genome-wide DNA methylome maps of EAC, UPSC, and normal
endometrium by applying a combined strategy of methylated DNA immunoprecipitation sequencing (MeDIP-seq)
and methylation-sensitive restriction enzyme digestion sequencing (MRE-seq). We discovered distinct genome-wide
DNA methylation patterns in EAC and UPSC: 27,009 and 15,676 recurrent differentially methylated regions (DMRs)
were identified respectively, compared with normal endometrium. Over 80% of DMRs were in intergenic and
intronic regions. The majority of these DMRs were not interrogated on the commonly used Infinium 450K array
platform. Large-scale demethylation of chromosome X was detected in UPSC, accompanied by decreased XIST
expression. Importantly, we discovered that the majority of the DMRs harbored promoter or enhancer functions
and are specifically associated with genes related to uterine development and disease. Among these, abnormal
methylation of transposable elements (TEs) may provide a novel mechanism to deregulate normal
endometrium-specific enhancers derived from specific TEs.
Conclusions: DNA methylation changes are an important signature of endometrial cancer and regulate gene
expression by affecting not only proximal promoters but also distal enhancers.Background
Endometrial cancer is the most common gynecologic
malignancy in the United States, with an estimated 47,130
new cases and 8,010 deaths annually [1]. Most cases of
endometrial cancer are endometrioid adenocarcinoma
(EAC), are of low grade, and are diagnosed at an early
stage, with a 5-year survival rate of greater than 85% [1].* Correspondence: Paul.Goodfellow@osumc.edu; twang@genetics.wustl.edu
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unless otherwise stated.Uterine papillary serous carcinoma (UPSC), an aggressive
histologic subtype of endometrial cancer, represents less
than 10% of all endometrial cancers. However, UPSC
accounts for more than 50% of recurrences and deaths
attributed to endometrial carcinoma [2,3]. EAC com-
monly displays near-diploid karyotypes, microsatellite
instability, and mutations in the PTEN, KRAS, and
CTNNB1 (β-catenin) genes. UPSC is characterized by
frequent TP53 mutation, Her-2/neu overexpression, and
an aneuploid karyotype [2,3].
Like many malignancies, endometrial cancer is a complex
disease driven by both genetic, epigenetic and environmen-
tal factors. DNA methylation has long been implicated in
the development and progression of tumors in variousLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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methylcytosine level and focal hypermethylation in
CpG islands near tumor-suppressor gene transcrip-
tional start sites were found in many different types of
cancers [7-10]. Among endometrial cancers, promoters
of important tumor suppressor genes including MLH1,
RASSF1A, PTEN, and APC, were found to be hyper-
methylated in EAC. However, methylation status of
these genes was largely unaltered in UPSC [11-16].
The divergent hypermethylation between these tumor
types might be caused by the significantly increased
expression of DNA methyltransferases DNMT1 and
DNMT3B observed in EAC, whereas expressions of
these enzymes were unchanged or even decreased in
UPSC [14,17].
Recently, The Cancer Genome Atlas Consortium
(TCGA) profiled DNA methylation of more than 300
endometrial cancer samples using array-based DNA
methylation platforms (HumanMethylation27 BeadChip
and HumanMethylation450 BeadChip), which interrogate
27,578 CpG sites and 482,421 CpG sites respectively [18].
Here we took a complementary approach to identify DNA
methylation changes unique to the two endometrial can-
cer subtypes in an unbiased fashion. Our strategy allowed
us to systematically measure DNA methylation levels of
more than 20 million CpG sites in the cancer genome in
an unbiased fashion with respect to intergenic and in-
tronic regions, including repetitive regions derived from
transposable elements. These regions are classically not
measured by array-based methods, such as the ones
employed by TCGA [19,20].
We generated complete DNA methylome maps for
endometrioid adenocarcinoma (EAC, three samples), uter-
ine papillary serous carcinoma (UPSC, three samples), and
normal endometrium (ten pooled samples) by integrating
data from methylated DNA immunoprecipitation sequen-
cing (MeDIP-seq) and methylation-sensitive restriction
enzyme sequencing (MRE-seq) [19-24]. Comparative ana-
lysis of these seven DNA methylomes identified cancer-
associated differentially methylated regions (DMRs) and
distinct EAC and UPSC genomic DNA methylation
patterns. Many methylation changes were found in CpG
island shores and these changes were predicted to affect
expression of nearby genes. We found demethylation
across large domains on the X chromosome in UPSC ac-
companied by decreased XIST expression. We also identi-
fied methylation differences at numerous miRNA gene
promoters that correlated with expression changes of the
associated miRNAs. We discovered that cancer type-
specific DMRs were enriched for not only promoters, but
also for enhancer elements. Moreover, specific transposable
elements (TEs), a rich genomic resource for potential en-
hancers [23,25-32], were affected by both de novo methyla-
tion and demethylation in cancer samples. Together, theseresults suggest that DNA methylation broadly impacts
cancer gene expression via regulation of promoters as well
as enhancers and TEs.
Results
Distinct global and focal DNA methylation signatures in
two types of endometrial cancer
DNA methylation changes have been reported in many
types of cancers and exhibit strong tissue-specific and
tumor type-specific characteristics [8,33,34]. DNA methy-
lation changes in the two subtypes of endometrial cancers,
endometrioid adenocarcinoma (EAC) and uterine papillary
serous carcinoma (UPSC), were recently reported by The
Cancer Genome Atlas Consortium [18]. This seminal
study provided the first insight into DNA methylation
changes at a genome-wide scale for this important cancer
using array-based platforms. Here we took a different strat-
egy, which is complementary to that of TCGA, to deeply
profile complete DNA methylomes of a small number of
tumor specimens using newly developed sequencing-based
epigenomics technology [19,20]. This strategy allowed us
to systematically discover DNA methylation changes in
cancer genomes without the biases imposed by microarray
methods. Findings based on analyzing a small number of
deeply profiled DNA methylomes (i.e., a discovery panel)
can then be validated using array-based approaches, which
can be applied to a much bigger number of samples (i.e., a
validation panel). In this study, we generated complete
DNA methylomes from six tumor samples (3 EACs and 3
UPSCs) and 1 pooled normal endometrium sample by ap-
plying methylated DNA immunoprecipitation sequencing
(MeDIP-seq) and methylation-sensitive restriction enzyme
sequencing (MRE-seq) [22]. We were able to comprehen-
sively measure DNA methylation levels of more than 20
million CpGs for each sample (Additional file 1: Table S1).
Sequencing data from the tumor samples were normalized
by their genomic copy number variations identified using
the Affymetrix SNP6.0 array.
Previous tumor DNA methylome studies have shown
global demethylation accompanied by focal hypermethyla-
tion in many cancers [7-10]. To understand the global pat-
tern of DNA methylation alterations in endometrial
cancer, we directly compared the overall distribution of
signal density from MeDIP-seq data at 5 kb resolution
across the seven methylomes. As expected, cancer samples
showed both hypomethylated and hypermethylated
changes compared to normal endometrium (Additional
file 2: Figure S1A). On average, 4.7% of the genome be-
came hypomethylated, and 1.5% became hypermethylated
in cancer (Additional file 1: Table S2). EAC and UPSC did
not exhibit dramatic differences in this analysis.
Our main goal was to identify local differentially meth-
ylated regions (DMRs) between cancer and normal
endometrium in a genome-wide fashion. To this end, we
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detects DMRs by integrating MeDIP-seq and MRE-seq
data [19]. In total, we identified 27,009 EAC-associated
DMRs and 15,676 UPSC-associated DMRs, with 6,606
DMRs in common between the two types of endometrial
cancer (EC-shared DMRs) (Figure 1A and Additional file 1:
Table S3). A complete list of these DMRs and links to the
WashU Epigenome Browser were provided on the accom-
panying website (Methods). In EAC, 68% of DMRs (18,294)
were hypermethylated and 32% (8,715) were hypomethy-
lated relative to normal endometrium. In contrast, 40%
(6,296) of the UPSC-associated DMRs were hypermethy-
lated and 60% (9,380) were hypomethylated (Figure 1B).Figure 1 Identification, annotation, and validation of DMRs in endom
carcinoma (UPSC). (A) 27,009 DMRs were identified in at least 2 EAC samp
samples (red: UPSC-DMRs). 6,606 DMRs were identified in both EAC and UP
(B) Percentage of hypermethylated (dark gray) and hypomethylated (light
enrichment for hypermethylated DMRs (left) and hypomethylated DMRs (ri
2,454 hypermethylated EC-shared DMRs in pre-classified (grade, microsatell
UPSC) and normal controls (green) in TCGA Infinium 450K data. DNA meth
group. Each boxplot represents the distribution of averaged methylation le
instability-high. MSS: Microsatellite stable. Asterisk: P < 1e-21 (Mann–Whitney
hypomethylated EC-shared DMRs in the same cohort (blue: EAC; red: UPSC) a
(F) Validation of EAC and UPSC type-preferred DMRs (tpDMRs) by TCGA Infini
grade 3 MSI-H-EAC (blue) and MSS-UPSC (red), compared to normal controls.
of UPSC (red) and EAC (blue). DNA methylation changes were calculated by s
the methylation level of each DMR in each cancer sample. Asterisk: P < 1e-21EAC and UPSC shared 4,597 hypermethylated and
2,009 hypomethylated DMRs (EC-shared DMRs). Previ-
ous studies have reported that two DNA methyltrans-
ferases (DNMT1 and DNMT3B) were more highly
expressed in EAC but repressed in UPSC [14,17].
Upregulation of the DNMTs was confirmed by qRT-
PCR in the three EAC samples we assayed. However, in
the UPSC samples, DNMT1, DNMT3A and DNMT3B
were not repressed, but had variable expression across
samples (Additional file 2: Figure S1B). Consistent with
our result, mRNA-seq data from TCGA also did not sup-
port previous studies: the three DNA methyltransfrases
exhibited significantly higher expression in patients withetrioid adenocarcinoma (EAC) and uterine papillary serous
les (blue: EAC-DMRs), 15,676 DMRs were identified in at least 2 UPSC
SC as endometrial cancer (EC) shared DMRs (orange: EC-shared DMRs).
gray) EAC-, UPSC-, and EC-shared DMRs. (C) Genomic feature
ght). (D) The DNA methylation level of 5,490 CpGs located within
ite state, and subtype) endometrial cancer samples (blue: EAC; red:
ylation level of each CpG site was averaged within the pre-classified
vels of 5,490 CpGs in cancer and controls. MSI-H: Microsatellite
U test). (E) The DNA methylation level of 1,093 CpGs located within 576
nd controls (green) as in (D). Asterisk: P < 1e-21 (Mann–Whitney U test).
um 450K data. Left: DNA methylation change of 2,002 EAC tpDMRs in
Right: DNA methylation change of 147 UPSC tpDMRs in same samples
ubtracting the averaged methylation level of the normal controls from
, octothorpe: P <1e-3 (Mann–Whitney U test).
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Figure S1C).
The genomic distribution of cancer-associated DMRs
was highly non-random (Additional file 1: Table S4). Over
70% of hypermethylated DMRs and 35% of hypomethy-
lated DMRs were located in open chromatin regions and
transcription factor binding sites, as defined by ENCODE
[35] (Additional file 2: Figure S2A). Hypermethylated
DMRs were strongly enriched for gene-related features,
including CpG islands, promoters, and exons (Figure 1C).
This is consistent with the notion that transcription-
related regions, in particular CpG islands, are frequent tar-
gets of DNA methylation changes in cancer. However,
these DMRs (CpG islands at promoters, exons, and UTRs)
only accounted for 40% of the total hypermethylated
DMRs in EACs. 60% of hypermethylated DMRs and 88%
of hypomethylated DMRs were located in introns and
intergenic regions (Additional file 2: Figure S2B). Strik-
ingly, when we examined the relationship between these
DMRs and annotated enhancers, we found that both
hypermethylated and hypomethylated DMRs were
strongly enriched for enhancer elements (Figure 1C). This
suggests that in addition to promoters and CpG islands,
enhancer elements can be a preferential target of DNA
methylation alteration in cancers.
Next, we validated that the endometrial cancer-
associated DMRs were recurrent by using Infinium 450K
data produced by The Cancer Genome Atlas (TCGA). The
Infinium 450K platform contains probes that span 6,583
CpG sites in 40% of 6,606 EC-shared DMRs (Additional file
2: Figure S2C). On average, over 85% EC-shared DMRs ex-
hibited significant DNA methylation differences (Methods)
between cancer patients and normal controls (Additional
file 2: Figure S2D). Patients of all pathologic groups dis-
played consistent DNA methylation levels within these
regions, robustly confirming our initial findings (Figure 1D
and 1E). Importantly, these recurrent EC-shared DMRs
exhibited hypo- or hypermethylation in low-grade EAC
patients to the same degree as that of high-grade patients
(Figure 1D and 1E), suggesting that abnormal DNA methy-
lation is shared across tumors of different grades, and can
potentially be detected in early stage of endometrial
carcinogenesis. Thus, these EC-shared, recurrent DNA
methylation changes could represent a unique epigenetic
signature for endometrial cancers.
In addition, we defined cancer type-preferred DMRs
(tpDMRs, see Methods). 3,443 EAC tpDMRs were present
in all three EAC samples but not in any UPSC sample,
and another 720 UPSC tpDMRs were present in all three
UPSC samples but not in any EAC sample. Of these, 57%
of EAC tpDMR regions and 21% of UPSC tpDMR regions
contained Infinium 450K CpG probes (Additional file 2:
Figure S2C), which allowed validation of our discovery
using TCGA data. Among these regions, 86% of EACtpDMRs and 89% UPSC tpDMRs showed significant DNA
methylation differences (Methods) between cancer patents
and normal controls (Additional file 2: Figure S2D).
Additionally, EAC and UPSC tpDMRs were enriched in
proximity to genes with different gene ontology terms
(Additional file 2: Figure S3A). Among TCGA patient sam-
ples, tpDMRs were confirmed and found to exhibit cancer
type-specific hypo- or hypermethylation status, suggesting
that these cancer type-preferred DMRs are recurrent with
respect to each cancer type (Figure 1F).
Distinct DNA methylation patterns at CpG islands, shores,
and gene promoters
There are about 28,000 CpG islands (CGIs) in the human
genome. About 70% of gene promoters are associated with
CGIs, and ~50% of CGIs contain annotated transcription
start sites (TSS). The majority of promoter CGIs are
unmethylated in somatic cells, although a significant por-
tion of gene body CGIs exhibit a conserved, tissue-specific
DNA methylation pattern [22,35,36]. DNA methylation of
CpG islands is often correlated with the repression of the
associated genes [37]. CpG islands frequently gain methy-
lation in cancer [38]. Hypermethylation of CGIs, especially
those associated with tumor suppressor genes, is consid-
ered a hallmark of many types of cancers [39,40].
Examination of CGI DNA methylation changes in the
two types of endometrial cancers revealed distinct signa-
tures for EAC and UPSC. Compared to normal endomet-
rium, we defined 1,476 and 553 hypermethylated CGIs for
EAC and UPSC respectively (Figure 2A). 495 CGIs were
hypermethylated in both types of endometrial cancer. 150
CGIs in EAC and 139 CGIs in UPSC exhibited reduced
DNA methylation compared to normal endometrial cells.
The two types of endometrial cancer can be clearly distin-
guished based on their CGI DNA methylation pattern
(Additional file 2: Figure S2E).
Compared to promoter CGIs, non-promoter CGIs were
more likely to undergo DNA methylation changes in
endometrial cancers (Table 1). 532 CGIs (in EAC) and
193 CGIs (in UPSC) out of ~6,000 intergenic CGIs, and
448 CGIs (in EAC) and 223 CGIs (in UPSC) out of ~8,000
gene body CGIs, were hypermethylated. In contrast, of
the ~13,000 promoter CGIs, only 496 and 137 were
hypermethylated in EAC and UPSC respectively. Hypo-
methylated CGIs were also predominantly located in non-
promoter regions, with 52 (in EAC) and 47 (in UPSC) in
intergenic regions, and 94 (in EAC) and 85 (in UPSC) in
gene bodies. Only 4 and 7 promoter CGIs were hypo-
methylated in EAC and UPSC respectively.
Next, we examined DNA methylation alterations in
CpG island shores (the flanking 1 kb around CGIs).
Abnormal DNA methylation of CGI shores was first
reported in colon cancer and found to affect expression
of the nearby genes [8]. In endometrial cancer, CGI
Figure 2 Methylation changes at CpG islands and promoters. (A) Numbers of CpG islands, 1 kb core promoter of RefSeq genes, and
promoters of tumor suppressor genes (TSG) with hypermethylated and hypomethylated alterations in EAC and UPSC. (B) Classification of DNA
methylation patterns in CpG islands and their shore regions: hypermethylation (orange) and hypomethylation (green) at CGI-only, both CGI and
shores, and shores-only. (C) Epigenome Browser views of four tumor suppressor gene (TSG) promoters with different DNA methylation patterns
across seven samples. MeDIP-seq tracks were displayed. The gene set view (−3 kb to +3 kb regions around TSS) was produced using the WashU
Epigenome Browser. Increased methylation level was highlighted by pink shading. (D) Gene expression analysis of the same four TSG in (C) with
hypermethylated promoters in normal controls and grade 3 pre-classified (microsatellite stability, subtype) endometrial cancers. Y-axis: RPKM value
based on mRNA-seq from TCGA. Asterisk indicates P <0.01, octothorpe indicates P <1e-5, Student’s t-Test.
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that were independent of changes in the CpG islands
(Figure 2B). We further classified DNA methylation
changes with respect to their patterns in both CGIs and
corresponding shores. In EAC, 805 of 1,476 hypermethy-
lated CGIs also displayed hypermethylation in their
shore regions, while 234 of 553 UPSC hypermethylated
CGIs had accompanying hypermethylated shores. Strik-
ingly, 1,581 EAC CGIs and 479 UPSC CGIs without
significant DNA methylation changes had flanking
hypermethylated shores. Additionally, 429 CGIs in EAC
and 452 CGIs in UPSC were specifically hypomethylated
in their shore regions but not in CGIs themselves
(Figure 2B). In EAC, 791 genes, including lncRNA genes,
were found around these 1,581 CGI shore-only hyper-
methylated CGIs, and 116 genes were close to 429
shore-only hypomethylated CGIs.
We then examined the DNA methylation status of 1 kb
core promoters around the TSS of annotated RefSeq genes
(Figure 2A). 1272 and 84 genes were hypermethylated orTable 1 DNA methylation alterations of CpG islands in EAC an
Inter






Hypermethylated CGI 47hypomethylated, respectively, at their core promoters in
EAC. These numbers were 258 and 96 in UPSC. This
result highlights the difference between the two types of
endometrial cancers. 218 gene promoters were hyper-
methylated in both tumor types, while 27 gene promoters
were hypomethylated in both. Gene function enrichment
analysis of these promoters returned no significantly
enriched terms related to endometrial tissue function
(Additional file 2: Figure S3B).
We observed 43 tumor suppressor genes (TSGs) [41]
with hypermethylated promoters in EAC, which is
consistent with our expectation that the silencing of
tumor suppressor genes is an important component of
carcinogenesis. In contrast, in UPSC we found only 10
tumor suppressor genes with hypermethylated promoters
(Additional file 2: Figure S4 and S5). As expected, the
majority of these tumor suppressor genes were repressed
in EAC (Additional file 2: Figure S4 and S5). Surprisingly,
some of these tumor suppressor genes were also repressed
in UPSC, even though the promoter regions wered UPSC
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well-known marker, the promoter of the MLH1 gene, is
usually highly methylated in microsatellite instability-high
(MSI-H) EAC, and was unmethylated in UPSC (Figure 2C
and Additional file 2: Figure S5C). However, RNA-seq data
from TCGA suggested that expression of MLH1 was also
repressed in some UPSC patients (Figure 2D). As expected,
hypermethylation of tumor suppressor gene promoters
was strongly associated with gene repression. For example,
KLF4 had a hypermethylated CGI shore and gene body
and was repressed in three groups of endometrial cancer
patients (Figure 2D). Similarly, the promoter of ALDH1A2
was hypermethylated and expression of this gene was re-
pressed in both EAC and UPSC. In contrast, the promoter
of PCDH10 was specifically methylated in EAC, and this
gene was respressed in EAC only (Figure 2C and 2D).
Unexpectedly, we found the core promoter regions of two
tumor suppressor genes, CDH1 and SFN, were demethy-
lated in three EAC samples (Additional file 2: Figure S6A).
Interestingly, these two genes were significantly upregu-
lated in all three groups of endometrial cancer patients
from TCGA (Additional file 2: Figure S6B). CDH1 and
SFN are important tumor suppressor genes whose loss of
function has been implicated in many types of cancers
[42-45]. Thus, their demethylation and increased expres-
sion underscores the complexity of regulatory events in
endometrial cancer.
Loss of X chromosome DNA methylation and XIST
expression in UPSC
One prominent signature distinguishing EAC and UPSC
was DNA methylation differences on the X chromosome.
More than 95% of DMRs on chromosome X were hypo-
methylated in UPSC (Figure 3A and Additional file 1:
Table S5). In contrast, only ~16% of chromosome X
DMRs were hypomethylated in EAC. Plotting MeDIP-seq
signal and MRE-seq signal at a large scale (500 kb reso-
lution) revealed loss of DNA methylation across the whole
X chromosome in UPSC, as evidenced by reduced
MeDIP-seq signal (~20%) and increased MRE-seq signal
(~60%) (Figure 3B). EAC also exhibited loss of DNA
methylation across the X chromosome, but to a much
lesser degree than UPSC. In contrast, similar analysis of
any autosome (e.g., chromosome 10) revealed no global
change of DNA methylation in either EAC or UPSC
(Additional file 2: Figure S7). We further examined
expression of XIST, the lncRNA critical for establishing
inactivation of the X chromosome, both in published data
and by performing qRT-PCR on our samples. XIST
showed reduced expression in both EAC and UPSC. Inter-
estingly, in microsatellite stable (MSS) type EAC samples,
the expression level of XIST was inversely correlated with
the tumor grade (cor = −0.19) (Figure 3C). qRT-PCR also
confirmed that XIST was down-regulated in four of sixendometrial cancer samples in our study (Additional file
2: Figure S1D). Finally, we examined the methylation level
of 9,620 CpGs (~0.8% of total CpGs on the X chromo-
some) in TCGA endometrial cancer samples profiled on
the Infinium 450K platform (Figure 3D). As expected,
compared to normal controls (mean 0.52), the patients
with grade 3 UPSC cancer type showed significantly lower
DNA methylation level (mean 0.45, p-value < 1e-7), and
the patients with grade 3 MSI-H EAC cancer type did not
show difference on these CpG sites (mean 0.51, p-value =
0.21). Interestingly, the TCGA samples with grade 3 MSS
EAC cancer type also show lightly reduced DNA methyla-
tion level on the X chromosome (mean 0.48, p-value < 1e-
5). These results suggest that global hypomethylation of X
chromosome and repressed XIST expression constitute a
strong signature for UPSC cancers.
DNA methylation changes of non-coding RNA genes
Our genome-wide DNA methylome maps also allowed
us to comprehensively assess DNA methylation changes
around non-coding RNA genes, including miRNA and
lncRNA. Epigenetic changes in promoters of non-coding
RNA genes could result in changes of their expression
levels, which subsequently could result in expression
changes of downstream protein coding genes in endo-
metrial cancer [46] and in changes of the epigenetic
landscape [47].
We examined DNA methylation patterns in promoter
regions around the TSS of miRNA gene clusters [48]. In
EAC, promoters of 24 miRNA gene clusters exhibited in-
creased DNA methylation, while 6 miRNA gene clusters
exhibited reduced DNA methylation. These two numbers
in UPSC were 9 and 2 (Additional file 2: Figure S8A).
Some of these miRNAs were reported to have significant
expression changes in endometrial cancer [46,49-51]. By
examining TCGA miRNA-seq data, we found that expres-
sion levels of certain miRNAs correlated with DNA
methylation changes in their promoters (Additional file 2:
Figure S8B and S8C). The microRNA cluster MIR200B-
MIR200A-MIR429 and cluster MIR200C-MIR141 showed
significant demethylation in endometrial cancer, and the
expression levels of these five microRNAs were signifi-
cantly increased in three groups of endometrial cancer
patients (Additional file 2: Figure S8C and S8D). The
MIR200 family was considered a tumor suppressor be-
cause of their inhibitory role in epithelial-mesenchymal
transition (EMT) in bladder cancer and breast cancer cell
lines [52-54]. Moreover, high expression of this cluster
was tightly correlated with survival rate in those tumor
types, and overexpression of these miRNAs inhibited
ovarian cancer cell motility [55]. In addition, the MIR200
family was reported to show significant upregulation in
endometrial carcinomas [50,56,57]. The exact functions of
MIR200 family members in gynecologic cancers, especially
Figure 3 (See legend on next page.)
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Figure 3 Loss of DNA methylation on the X chromosome. (A) Distribution of hypermethylated (gray) and hypomethylated DMRs (blue) on all
chromosomes in EAC (left) and UPSC (right). (B) Global DNA methylation changes on the X chromosome. MeDIP-seq and MRE-seq RPKM values
of seven samples were calculated at 500 kb resolution across the X chromosome. The averaged RPKM fold changes (cancer/normal) of each type
(3 EACs and 3 UPSCs) were log2-transformed and plotted along with the X chromosome coordinate. (C) XIST expression in normal controls and
pre-classified (grade: G1, G2, G3; microsatellite state, and subtype) endometrial cancer samples. Y-axis: calculated RPKM value based on mRNA-seq
from TCGA. Asterisk indicates P <0.01, Student’s t-test. (D) DNA methylation distribution of 9,620 CpG sites on the X chromosome in pre-classified
grade 3 (microsatellite state, and subtype) uterine corpus endometrial cancer samples (light blue: MSI-H type EAC patients; dark blue: MSS type
EAC patients; red: MSS type UPSC patients. Infinium 450K platform) and normal controls (green, Infinium 450K platform). For each CpG site, the
averaged DNA methylation level was calculated within the pre-classified group, and each boxplot represents distribution of the averaged methylation
level of all 9,620 CpGs of the cancer groups and the normal controls. CpG sites with no value in any sample were removed. MSI-H: Microsatellite
instability-high. MSS: Microsatellite stability. The Mann–Whitney U test was performed respectively for each cancer group when compared to
normal controls.
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Interestingly, even with strongly hypermethylated pro-
moters, some miRNAs exhibited upregulated expression
level, including MIR25, MIR93, MIR99B, MIR324,
MIR106B, and MIR3074 (Additional file 2: Figure S8E).
The regulatory relationship between promoter hyperme-
thylation and microRNA expression is likely complex and
needs further investigation.
Hundreds of lncRNA genes [58] also underwent
DNA methylation changes in our endometrial samples
(Additional file 2: Figure S8A). Specifically, 621 and 168
lncRNA genes had hypermethylated promoters in EAC
and UPSC respectively, compared to normal endomet-
rium. Of these, 144 were in common between the two
cancer types. The numbers of hypomethylated lncRNA
genes were 207 for EAC and 245 for UPSC, with 68 in
common. With the exception of classic examples such as
XIST, H19, and HOTAIR, the widespread regulatory roles
of lncRNAs are only recently being revealed [59]. The
roles of lncRNAs and consequences of their abnormal
DNA methylation in endometrial carcinogenesis remain
to be elucidated. However, interesting candidate genes
emerged from our analysis. For example, maternally
expressed gene 3 (MEG3), a tumor suppressor non-coding
RNA [60], was highly methylated at its promoter region in
EAC. This was associated with significantly downregulated
MEG3 mRNA (Additional file 2: Figure S9). Re-expression
of MEG3 was found to induce TP53 activation, and inhib-
ited tumor cell proliferation in culture and colony forma-
tion in soft agar [60-64].
DNA methylation changes were enriched in functional
promoter and enhancer elements
The majority of the differentially methylated regions were
located in intergenic or intragenic regions, while a small
fraction (11% in EACs, and 5% in UPSCs) overlapped
directly with annotated gene promoters. Previous work
reported that normal tissue developmental processes could
be used to model tumor developmental states [65]. Here
we examined endometrial cancer DMRs in the context of
their epigenetic status in embryonic stem cell (ESC) H1 tomap the dynamics of DNA methylation changes [19]. We
defined four DNA methylation patterns across ESC, nor-
mal endometrium, and endometrial cancer (Figure 4A):
MMU,Methylated in ES cells,Methylated in normal endo-
metrium, but Unmethylated (or hypomethylated) in can-
cer; MUM, Methylated in ES cells, Unmethylated in
normal endometrium, and Methylated in cancer; UMU,
Unmethylated in ES cells, Methylated in normal endomet-
rium, and Unmethylated in cancer; and UUM, Unmethy-
lated in ES cells, Unmethylated in normal endometrium,
and Methylated in cancer. We reasoned that the genomic
distribution and functions of genes associated with differ-
ent patterns might help to reveal insights into endometrial
carcinogenesis in the context of normal development. We
annotated the potential regulatory function of these differ-
ent categories of DMRs with the chromatin state maps
defined by chromHMM using nine cell lines [66]. Interest-
ingly, the majority of the UUM DMRs were annotated as
promoters, whereas the majority of the MUM DMRs were
annotated as enhancers (Figure 4B).
We then examined the functional enrichment of genes
near these four different categories of DMRs (Figure 4C
and Additional file 2: Figure S10A). Significantly, genes
near pattern MUM enhancer DMRs in both types of
cancer were strongly enriched for terms related to uter-
ine development and disease. Consistent with our previ-
ous annotation of tissue-specific enhancers [19], this
result suggested that these DMRs might encode uterine-
specific regulatory elements that became unmethylated
and activated during normal development and differenti-
ation. Their hypermethylation in endometrial cancer
might contribute to the loss of endometrial tissue type
identity and to the gain of stem cell-like characteristics
often observed in cancers. In contrast, pattern MMU
DMRs enriched for functions specific to tissues unre-
lated to endometrium. For example, in EAC, genes re-
lated to hindbrain morphogenesis and mammary gland
epithelium development were enriched near MMU
DMRs. In UPSC, we found enrichment of genes related
to lung, muscle, and kidney development. In addition,
we found genes related to estrogen response, consistent
Figure 4 (See legend on next page.)
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Figure 4 DNA methylation alterations are enriched in functional promoters and enhancers. (A) Four DNA methylation state patterns
across embryonic stem cells (H1), normal endometrium (NE), and endometrial cancer (EC). Red block: methylated state; empty: unmethylated
state. (B) Fractions of DMRs with different DNA methylation state patterns in EAC (left) and UPSC (right). DMRs with patterns MMU (yellow), UUM
(green), and MUM (blue) were annotated by chromHMM for their potential regulatory functions (purple: promoter; orange: enhancer state; gray:
other states). (C) Functional enrichment of DMRs in pattern MMU, UUM, and MUM by GREAT analysis (purple: DMRs annotated as promoters by
chromHMM; orange: DMRs annotated as enhancers by chromHMM). X-axis denotes negative log10-transformed p-value. (D) Epigenome Browser
views of representative DMRs with different methylation state patterns. MeDIP-seq signal tracks were displayed. Increased and decreased methylation
levels were highlighted by pink and green shading, respectively. Left (pattern MMU): a DMR overlapped with transposable element MER52A was
methylated in normal endometrium, H1 ESC, PBMC, and fetal brain, but unmethylated in breast myoepithelial cells. In EAC and UPSC, the element was
hypomethylated, indicated by decreased MeDIP-seq signal. Middle (pattern UUM): a DMR overlapped with CGI of lncRNA LOC100130992 was
unmethylated in normal endometrium, H1 ESC, and PBMC, but methylated in breast myoepithelial and fetal brain. The element was hypermethylated
in EAC and UPSC. Right (pattern MUM): a DMR overlapped with CGI-shore of ADCY3 was methylated in all other tissues except in normal endometrium.
In EAC and UPSC, this element was hypermethylated. (E) TIAM2 expression in normal controls and grade 3 pre-classified (microsatellite state, and subtype)
endometrial cancer patients samples. Y-axis: calculated RPKM value based on mRNA-seq from TCGA. Asterisk indicates P <0.01, caret indicates P <0.05,
Student’s t-Test. (F) The MER52A element enhanced luciferase reporter gene expression in HEK-293T cells. Blue: mini promoter; orange:
MER52A+mini promoter.
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[67,68]. This data suggested a very different but comple-
mentary mechanism for cancer gene deregulation: these
MMU DMRs might represent a broad array of tissue- or
cell type-specific regulatory sites important for develop-
ment and differentiation. Their demethylation in endomet-
rial cancer might simultaneously deregulate tissue-specific
genes important for other tissues, thereby contributing to
the loss of endometrium specificity. The UUM pattern, on
the other hand, was associated with functions related to
carcinogenesis in general, including RNA polymerase II,
nucleic acid-binding transcription factors, tumor suppres-
sor genes, direct effectors of TP53, cell-substrate adherent
factors, and agents of cellular response to cytokine stimuli
(Figure 4C and Additional file 2: Figure S10A). Finally, very
few DMRs exhibited the UMU pattern, which was
predicted to be associated with embryonic development
(Additional file 2: Figure S10A).
We highlighted a few examples with different methyla-
tion patterns (Figure 4D). A DMR with pattern MMU
overlapped a copy of transposable element MER52A. This
DMR was predicted to be an enhancer by chromHMM
[66] and was located in the intron of TIAM2 and 2.7 kb
upstream of a gene-body alternative promoter. The DMR
was highly methylated in ESC and normal endometrium,
but was hypomethylated in endometrial cancer, particu-
larly in UPSC. This element was also hypomethylated in
breast myoepithelial cells but methylated in blood cells
and brain tissues, consistent with the hypothesis that
MMU pattern was associated with tissue-specific en-
hancers (Figure 4D). TIAM2 regulates focal adhesion, and
knockdown of this gene leads to a reduced rate of cell
migration [69]. By examining TCGA mRNA-seq data, we
found that the expression level of TIAM2 was upregulated
in both EAC and UPSC, compared to normal controls
(Figure 4E). Importantly, we did not find DNA methyla-
tion changes at the promoter region of TIAM2. Based on
a luciferase reporter assay, this MER52A elementincreased reporter gene expression about 9-fold in HEK-
293T cells (Figure 4F). These results suggested that de-
methylation of this transposable element could activate its
enhancer function and increase TIAM2 expression, poten-
tially contributing to cancer cell migration and endomet-
rial carcinogenesis. In another example, a pattern UUM
DMR was identified in the promoter region of lncRNA
LOC100130992. The DNA methylation status of this
promoter was tissue-specific: methylated in breast myoe-
pithelial cells and brain tissue, but unmethylated in H1
ESC, normal endometrium cells, and peripheral blood
monocytes (Figure 4D). Numerous promoter DMRs with
pattern MUM were predicted to play roles in normal
endometrial functions. For example, the ADCY3 promoter
was specifically hypomethylated in normal endometrium,
but its associated CpG island shore was highly methylated
in EAC and UPSC. ADCY3 encodes adenylyl cyclase 3,
which catalyzes the formation of the secondary messenger
cyclic adenosine monophosphate (cAMP). cAMP stimu-
lates vascular endothelial growth factor (VEGF) secretion
by human endometrial stromal cells [70] and mediates
progesterone-dependent decidualization of the human
endometrium [71]. ADCY3 expression was indeed re-
pressed in both EAC and UPSC (Additional file 2: Figure
S10B).
Bidirectional DNA methylation alteration on TE-derived
enhancers
We noted that the TIAM2 intragenic enhancer was within
a transposable element. TEs make up nearly half of the
human genome, but they have long been considered “junk
DNA” that does not systematically contribute to normal
cellular function [25,72]. Deregulation of TEs has, how-
ever, been proposed to be an important contributor to
carcinogenesis. TEs, especially LINE-1 retrotransposons,
are hypomethylated in many types of cancers [73-78]. We
systematically evaluated the DNA methylation state of all
TEs in the human genome that could be uniquely mapped
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30% of hypermethylated DMRs and more than 40% of
hypomethylated DMRs in both types of endometrial cancer
were within TEs (Figure 5A). These changes in methylation
status were enriched for specific TE families and subfam-
ilies. For example, the LINE-1 family was hypomethylated
in both EAC and UPSC (Additional file 2: Figure S11), con-
sistent with observations made in other cancer types
[73-75]. We calculated enrichment of TE subfamilies in
endometrial cancer DMRs. Four subfamilies were signifi-
cantly more likely to be hypermethylated in EAC or UPSC
(enrichment > 5-fold), whereas 13 subfamilies were signifi-
cantly more likely to be hypomethylated in EAC or UPSC
(enrichment > 5-fold) (Figure 5B).
We further investigated individual TE copies that
exhibited a change in DNA methylation. For the purpose
of illustration, we used LTR6A and MER52A. We com-
puted methylation levels of individual copies of LTR6A
and MER52A in EAC and UPSC (RPKM values from
MeDIP-seq and MRE-seq data normalized to the valuesFigure 5 DNA methylation alterations of transposable elements. (A) P
UPSC. (B) DMR enrichment within transposable element subfamilies. Enrich
five genomic copies of LTR6A and their methylation levels across multiple s
methylation levels were highlighted by pink shading. These elements were
H1 ESC, PBMC, breast myoepithelial cells, and fetal brain, and hypermethyla
copies of MER52A and their methylation levels across multiple samples. Me
were highlighted by green shading. These elements were methylated (norma
(breast myoepithelial cells) in normal cells, but were hypomethylated in EAC ain normal endometrium). About 70% of LTR6A elements
exhibited increased MeDIP-seq and decreased MRE-seq
signal, reflecting hypermethylation (Additional file 2:
Figure S12A). In contrast, around 70% of MER52A
elements had decreased MeDIP-seq and increased MRE-
seq (Additional file 2: Figure S12B). The most highly
hypermethylated LTR6A copies were found to be differ-
entially methylated across different tissues, and were
annotated as enhancers by chromHMM (Figure 5C). In
contrast, the most highly hypomethylated MER52A copies
exhibited strong methylation in all five normal tissues
(including H1 ESC, breast, blood, brain, and endomet-
rium) (Figure 5D).
Our results indicate that TEs may be important regula-
tory elements, particularly enhancers, in carcinogenesis.
Transposable elements have been shown to wire gene
regulatory networks during evolution [25,27-30], and TE
subfamilies with tissue-specific hypomethylation also
function as enhancers, which may associate with tissue
identity [23]. How these transposable elements contributeercentage of DMRs overlapping transposable elements in EAC and
ments > 5-fold were shaded in red. (C) Epigenome browser view of
amples. Only MeDIP-seq signal tracks were included. Increased
unmethylated in normal endometrium, differentially methylated across
ted in EAC and UPSC. (D) Epigenome browser view of five genomic
DIP-seq signal tracks were displayed. Decreased methylation levels
l endometrium, H1 ESC, PBMC, and fetal brain) or partially methylated
nd UPSC.
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Moreover, in contrast to the common belief that most TEs
are methylated and repressed in somatic cells [75,79,80],
the discovery that a significant fraction of TEs were
unmethylated in normal tissues but methylated in cancer
suggests that some TEs play important roles in maintaining
normal cell states and sustaining regular cellular physio-
logical processes. These TE-mediated processes were likely
disrupted in cancer cells. The widespread abnormal DNA
methylation of transposable elements in cancer could re-
flect rewiring of gene regulatory networks during carcino-
genesis. In normal tissues, some TEs were unmethylated
and acted as tissue-specific enhancers. When these TEs
were hypermethylated in cancer cells, they were silenced
and this could have contributed to the down-regulation or
silencing of target genes. On the other hand, hypomethyla-
tion of normally methylated TEs could function as cryptic
enhancers or promoters [20], contributing to the upregula-
tion of target oncogenes.
Discussion
Changes in DNA methylation have been shown to play
roles in carcinogenesis and cancer progression in many
malignancies [4,8,9] including endometrial cancer [11,12].
Previous studies have identified many genes exhibiting ab-
normal DNA methylation changes in endometrial cancer
[11-14,16,81]; however, these studies, including the most
recent and comprehensive mapping of DNA methylation
in endometrial cancers by TCGA [18], were all focused on
selected genomic regions (e.g., promoters and CpG
islands) and CpG sites. Our study systematically investi-
gated the complete DNA methylome in two clinically dis-
tinct types of endometrial cancer, EAC and UPSC, as well
as normal endometrium, providing the first whole-
genome DNA methylation map for this important disease.
We observed significant DNA methylation changes in
both types of endometrial cancer, which displayed both
shared and cancer subtype-preferred DNA methylation
signatures. Endometrial cancer-shared DMRs defined a
specific signature of endometrial cancer that is confirmed
by TCGA endometrial cancer methylation data (Figure 1D
and 1E). In UPSC, which previously was thought to have
infrequent DNA methylation changes and low DNMT ex-
pression, we identified numerous novel DNA methylation
alterations (95% of 15,657 UPSC DMRs) in non-promoter
regions (intergenic and intragenic). These results demon-
strate the importance of applying sequencing-based,
whole-genome approaches (i.e., MeDIP-seq and MRE-seq)
to comprehensively map DNA methylation changes in
cancers. In contrast, the Infinium HumanMethylation450
BeadChip, a popular genome-wide platform used by
TCGA and many others, only interrogates about 1.7%
(485,000) of the 28 million CpGs in the human genome.
In our study, more than 40% of the hypermethylatedDMRs and 75% of the hypomethylated DMRs we identi-
fied were not covered by any Infinium probes; additionally
only about 25% of the hypermethylated DMRs and 9% of
the hypomethylated DMRs had more than two probes
(Figure 6).
Despite being much more comprehensive, sequencing-
based DNA methylome technologies are still cost inhibi-
tory for directly profiling the large cohort of specimens
that is often required to obtain power to detect most epi-
genetic events significantly associated with cancer. Thus,
we advocate a strategy that combines deep profiling of a
small number of samples (in this study, three samples per
cancer type) followed by validation in a large cohort
(in this study, we used publically available TCGA data).
The strong validation results (Figure 1D-1F) suggest that
our strategy is able to capture recurrent abnormal DNA
methylation and provide a much more complete picture
of the epigenetic landscape in endometrial cancer.
CpG islands and gene promoters are classic targets of
DNA methylation changes in carcinogenesis. In endo-
metrial cancer, we confirmed that hypermethylation was
strongly enriched in transcription-related regions, in-
cluding CGIs and promoters. Over 65% of CGIs with
altered methylation were located in intergenic and intra-
genic regions, suggesting that alternative promoters may
be frequent targets of DNA methylation change in can-
cers [20,22]. In addition, CGI shores were frequently
affected by DNA methylation alterations (Figure 2A and
Additional file 2: Figure S6A) [8,34]. Similar to CGIs,
epigenetic changes at these potential regulatory regions
may also regulate expression of nearby genes (Figure 2D,
Additional file 2: Figure S6B). Epigenetic silencing of
tumor suppressor genes (TSGs) is an important mech-
anism of carcinogenesis. In our study, many TSGs had
hypermethylation in their core promoter regions, but
interestingly, two tumor suppressor genes (CDH1 and
SNF) were found to have hypomethylated promoters and
increased mRNA expression. Hypomethylation of the
SNF promoter was also reported in lung and prostate
cancer [42,43]. However, the methylation pattern of
CDH1 seems to be much more complex in endometrial
cancer. Hypermethylated CDH1 promoter and repressed
CDH1 expression were reported in some endometrial
cancer cases [82,83]. Our approach revealed a hypomethy-
lated DMR located in the 5’ shore region of the CDH1
promoter CpG island. This discovery was confirmed by
TCGA Infinium 450K data: significant demethylation was
detected by 2 CpG probes located in the DMR, but 8
nearby CpG probes within the CpG island did not detect
any DNA methylation change (Additional file 2: Figure
S6C). These results suggest that a demethylated promoter
and increased expression of CDH1 might be a common
feature of endometrioid adenocarcinomas. The role of
CHD1 in endometrial cancer remains to be determined.
Figure 6 Infinium 450K array probe representation for DMRs. For EAC DMRs, 41% of hypermethylated and 76% of hypomethylated regions
were not represented by Infinium 450K probes (light gray). For the UPSC DMRs, 49% of hypermethylated and 75% of hypomethylated regions did
not contain Infinium 450K probes (light gray).
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the X chromosome is randomly inactivated in female
cells. The X-inactivation process is initiated by the ex-
pression of XIST, a mono-allelically expressed long non-
coding RNA. High allelic expression of XIST on the in-
active X establishes the inactivation state [84-88]. DNA
methylation and repressive histone modifications, such as
H3K27me3 and H3K9me3, play essential roles in main-
taining the inactivated state [85,89-93]. The link between
X chromosome epigenetic changes and female reproduct-
ive cancers was evident in a subset of breast and ovarian
cancers [94]. In UPSC, we observed significant demethyla-
tion across the entire X chromosome, accompanied by
down-regulated XIST expression. Interestingly, the expres-
sion level of XIST was also decreased in EAC and corre-
lated with tumor grade (Figure 3C). In contrast to UPSC,
we did not observe a significant global hypomethylation
pattern in our three EAC samples. TCGA data revealed
no global changes in the MSI-H type EAC, but a small but
significant global hypomethylaton in the MSS type of EAC
and in UPSC (Figure 3D). The Infinium 450K array only
interrogates ~0.8% CpG sites on the X chromosome and
is biased towards CpG sites in promoters and CpG
islands. Thus, further validation is necessary to confirm
the status of X chromosome DNA methylation. However,
our results suggest that this significant sex chromosome
demethylation could be a distinguishing signature between
EAC and UPSC and might be associated with microsatel-
lite stability. In ovarian cancer, a strong association was
found between down regulated XIST expression and de-
creased time to recurrence in patients treated with Taxol[95]. Although the mechanisms underlying XIST down-
regulation and the biological significance of DNA methy-
lation loss remain to be determined, we hypothesize that
repressed XIST expression and DNA demethylation might
contribute to the aggressive behavior in endometrial can-
cer, especially in UPSC.
Up to 80% of the human genome is transcribed but only
~2% encodes proteins [96-98]. In the past decade, numer-
ous small and long non-coding RNAs (lncRNA) have been
shown to be important regulators in both normal develop-
ment and disease [59,99]. We observed DNA methylation
alterations at many miRNA promoters. The expression of
some miRNAs was correlated with DNA methylation
states. For example, the MIR200A-MIR200B-MIR429 clus-
ter, which are tumor suppressor genes in many cancers,
showed strong promoter demethylation in EAC and UPSC,
with significantly upregulated expression (Additional file 2:
Figure S8C and S8D). We also observed DNA methylation
alterations at promoters of hundreds of lncRNA genes. The
precise biological function of these miRNAs and lncRNAs
and the significance of their DNA methylation changes in
endometrial cancers remain to be determined. However,
their identification underscores the importance of having a
comprehensive catalog of cancer-associated DNA methyla-
tion changes across the whole genome.
DNA methylation exhibits strong tissue specificity,
which is tightly programmed during embryonic develop-
ment [100-104]. Alteration of DNA methylation in cancer
radically changes the normal epigenetic landscape and
results in loss of tissue specificity or cell identity [40]. For
example, colorectal cancer DMRs had a striking overlap
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possibly disrupting tissue-specific regulatory programs [8].
By including DNA methylome data from embryonic stem
cells, we identified a subset of endometrial cancer DMRs
showing specific demethylation in normal endometrium,
but high methylation in both H1 ESC and endometrial
cancer (DNA methylation pattern MUM). These DMRs,
which accounted for 30% of EAC DMRs and 20% of UPSC
DMRs, showed a strong functional enrichment for genes
related to uterine embryonic development and disease.
Moreover, more than half of these MUM DMRs and
~25% of MMU and UUM DMRs were predicted to be
distal enhancers (Figure 4B) that were deregulated in
endometrial cancers. These results highlight that in
addition to gene promoters, enhancers are a major target
of DNA methylation changes in endometrial cancer.
Interestingly, a significant fraction of deregulated en-
hancers were derived from transposable elements (TEs):
more than 30% of hypermethylated and 40% of hypo-
methylated DMRs harbored TEs. TEs have classically
been understood to have high methylation in normal
somatic cells and undergo global demethylation in can-
cers [10,73-75]. However, recent data have demonstrated
that TEs play many important roles in normal biology,
especially in wiring gene regulatory networks during
evolution [25,27-30], and contributing to the establish-
ment of tissue-specific gene regulation in development
[23]. A breast-specific hypomethylated LTR element,
MER52A, was found in the intron of the oncogenic
TIAM2 gene. This element was methylated in normal
endometrium but demethylated in endometrial cancer
(Figure 4D), and its enhancer function was validated
using a reporter gene assay (Figure 4F). Our study sug-
gested that DNA methylation in TEs might have a much
more profound impact in cancer than previously be-
lieved. Consistent with our recent discovery [23], we
identified unmethylated TEs in normal endometrium
that may serve as tissue-specific enhancers. Some of
these TE-derived, tissue-specific enhancers were hyper-
methylated and presumably silenced in endometrial can-
cer samples. In contrast, some normally methylated TEs
(and TE-derived enhancers, possibly specific for other
tissues) became hypomethylated in endometrial cancer.
Disruption of normal DNA methylation of TE-derived
and tissue-specific enhancers might be a novel mechan-
ism to facilitate loss of tissue identity, acquisition of new
cell type phenotypes, and to contribute to tumor devel-
opment and progression (Figure 7). Complex rewiring of
gene networks by epigenetic alterations might play a
critical role in endometrial carcinogenesis. However,
additional data, including a comprehensive annotation of
the enhancer landscape in normal endometrial cells and
in endometrial cancers, are needed to further elucidate
this important mechanism.Conclusions
We systematically investigated the complete DNA
methylome in two clinically distinct types of endometrial
cancer, EAC and UPSC, as well as normal endometrium,
providing the first whole-genome DNA methylation map
for this common and deadly disease. From these data-
sets, we identified tens of thousands of DMRs specific to
the two cancer subtypes (endometrioid adenocarcinoma,
or EAC, and uterine papillary serous carcinoma, or
UPSC), and common to both cancer subtypes. We esti-
mate that more than 2/3 of the DMRs we identified
could not be discovered by using current array-based
platforms. Many methylation changes were found in
CpG island shores and were associated with expression
changes of nearby genes. We observed large-scale DNA
demethylation of chromosome X in UPSC accompanied
by decreased XIST expression. Most significantly, we dis-
covered that the majority of DMRs harbor regulatory
functions including promoters and enhancers that are
important to developmental and pathological changes of
the uterus. Among these, remethylation of transposable
elements in cancers might provide a novel mechanism
to deregulate normal endometrium-specific enhancers
derived from specific transposable elements. Our results
demonstrate that DNA methylation changes are an
important signature of endometrial cancer and regulate
gene expression by affecting not only proximal pro-
moters, but also distal enhancers, including those de-
rived from transposable elements.Methods
Website
A complete list of endometrial cancer associated DMRs
and links to the WashU Epigenome Browser [105,106]
are provided at the following website:
http://epigenome.wustl.edu/Cancer_Epigenome/.Sample collection
All primary endometrial tumors and normal endometrium
specimens analyzed were collected as part of IRB-approved
studies (Washington University Medical Center Human
Research Protection Office protocols HRPO-91-507, −93-
0828, −92-242, and −10-1245), with participants’ written
informed consent. Histologic grading and typing were
performed by gynecologic pathologists. Staging was deter-
mined using 1988 criteria from the International Federation
of Gynecology and Obstetrics. Details of sample informa-
tion were described in Additional file 1: Table S6. Tissue
specimens and blood were obtained at the time of surgery
and stored at −70°C until nucleic acids were extracted. All
primary tumors evaluated had ≥ 70% neoplastic cellularity.
Normal endometrium cells were collected from 10 healthy
Figure 7 Proposed model for loss of tissue identity during carcinogenesis associated with epigenetic alterations at enhancers. Left:
Normal DNA methylation at enhancers mediates tissue-specific gene silencing and activation in normal cells. Right: DNA methylation alteration at
enhancers in cancer cells induces abnormal regulation and subsequent changes in expression of tissue-specifically silenced or activated genes,
leading to loss of tissue identity.
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pooled together.Library construction, sequencing and mapping
Genomic DNA from tumor tissues and normal endomet-
rium was extracted using the DNeasy Tissue kit (Qiagen,
Valencia, CA). MeDIP and MRE sequencing libraries were
constructed as previously described [22]. Sequencing
reads were aligned to hg19 with Bowtie [107]. MRE reads
were normalized to account for differences in enzyme effi-
ciency and scoring consisted of tabulating reads with
CpGs at each fragment end [22].
MeDIP-seq data and MRE-seq data of normal tissues,
including H1 ESC, PBMC, breast myoepithelial, and fetal
brain, were obtained from previous work [19]. This in-
formation was listed in Additional file 1: Table S7.Affymetrix SNP array 6.0 processing
Affymetrix Genome-Wide SNP Array 6.0 was used for de-
tection of copy number changes in this study. Genomic
DNA was extracted from endometrial cancer samples and
matched peripheral blood mononuclear cells (PBMC)
using the DNeasy Tissue kit (Qiagen, Valencia, CA). The
Affymetrix Genome-Wide SNP Array 6.0 standard
protocol was performed as recommended by the manu-
facturer. 500 ng of total genomic DNA were analyzed
in the Genome Technology Access Center at Washing-
ton University in St. Louis. Data were analyzed by
Genotyping Console™ (GTC) Software 4.1.1 following
the manufacturer’s instructions.RNA isolation
RNA was extracted from frozen endometrial cancer tissues
and pooled normal endometrium using Trizol reagent (Life
Technologies) following the manufacturer’s instructions
with an additional phenol/chloroform extraction to exclude
protein contamination. Trace DNA was removed by treat-
ment with TURBO DNA-free Kit (Life Technologies).
Quantity and quality of isolated RNA was measured and
evaluated by UV spectrophotometer and gel electro
phoresis.
Quantitative real time PCR (qRT-PCR) analysis
The qRT-PCR analyses were performed using the Super-
Script VILO cDNA Synthesis Kit (Life Technologies) with
iTaq Universal SYBR Green Supermix (Bio-Rad). 500 ng
total RNA was used in a 20 ul reverse transcription reac-
tion. The cDNA obtained was diluted to a total volume of
100 ul and stored at −20°C. The primers for human
DNMT1, DNMT3A, DNMT3B [108], DNMT2 [109], XIST
[110] and candidate human housekeeping gene 18S rRNA
[111] were used for amplification of the target genes in
normal endometrium and endometrial cancer tissues. All
primers were synthesized by Integrated DNA Technolo-
gies. The qRT-PCR was performed in a 20 ul reaction con-
sisting of 2 ul diluted cDNA, 0.2 uM of each primer and
10 ul iTaq Universal SYBR Green Supermix. All amplifica-
tions were carried out in a Bio-Rad CFX96 Real-Time
PCR Detection (Bio-Rad) with denaturation at 95°C for
30 s, followed by 40 cycles at 95°C for 5 s and 60°C for
30 s. A melting curve analysis was performed for each run
to confirm the specificity of amplification and lack of pri-
mer dimers. The qRT-PCR experiments were always run
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genes were quantified using the 2-ΔΔCT equation for
endometrial normal and cancer tissues. Mean CT of nor-
mal endometrium was used as the calibrator sample.
DMR identification
The methylMnM package (http://epigenome.wustl.edu/
MnM/) was utilized to identify differentially methylated
regions (DMRs) in the R 2.15 environment between the
DNA methylome of normal endometrium and the DNA
methylome of each cancer sample. Default parameters
were used, and a statistical cutoff of q-value < 1e-5 was
applied to select DMRs from each pair-wise comparison at
a resolution of 500 bp. EAC or UPSC DMRs were defined
such that the same genomic region must have been called a
DMR and have the same direction of DNA methylation
change in at least two out of the three cancer vs. normal
pairwise comparisons. Endometrial cancer shared DMRs
(EC-shared DMRs) were defined as DMRs that were both
EAC DMRs and UPSC DMRs and had same direction of
DNA methylation change in both types of cancers com-
pared to the pooled normal sample. EAC type-preferred
DMRs (tpDMRs) were defined as DMRs in all three EAC
samples but not in any UPSC sample; UPSC tpDMRs were
defined as DMRs in all three UPSC samples but not in any
EAC sample. The same procedure and statistical cutoff
were used to define DMRs between H1 ESC and normal
endometrium.
Genomic features
RepeatMasker annotations, CpG islands, and RefSeq
Gene coding loci features were all downloaded from the
UCSC Genome Browser [112,113]. 1 KB core promoters
were defined as 1 kb around the most 5’ transcription
start site (500 bp upstream and 500 bp downstream of
TSS) of any RefSeq gene record. microRNA loci were
downloaded from mirBASE. The microRNA gene cluster
TSSs were download from mirStart (http://mirstart.mbc.
nctu.edu.tw/). lincRNA loci were download from the
Human lincRNA Catalog (http://www.broadinstitute.
org/genome_bio/human_lincrnas/).
TCGA DNA methylation data
Processed DNA methylation data of uterine corpus endo-
metrial carcinomas (Infinium HumanMethylation450
BeadChip platform) was downloaded from The Cancer
Genome Atlas (TCGA) (http://cancergenome.nih.gov/).
Quantile normalization was performed across all samples.
The beta-value of each probe within DMRs was isolated
for further analysis in the R 2.15 environment. Sample
histology information was obtained from the supplemen-
tary materials of Kandoth et al. [18]. Sample details were
described in Additional file 1: Table S8.TCGA RNA expression data
Processed mRNA-seq and miRNA-seq data (normalized
read counts for each gene, analysis version 2) of uterine
corpus endometrial carcinomas (Illumina GA and Illumina
HiSeq platform) were downloaded from The Cancer Gen-
ome Atlas (TCGA) (http://cancergenome.nih.gov/). RPKM
(Reads per kilobase per million) values were computed for
each gene using TCGA’s mRNA sequencing data (analysis
version 2). The lengths of transcripts were obtained from
the NCBI gene bank. Quantile normalization was per-
formed across all samples. RPM (Reads per million) values
for each microRNA gene were computed using TCGA’s
microRNA sequencing data. All analyses were performed
in the R environment (Version 2.15). Sample details were
provided in Additional file 1: Table S8.
Validation of DMRs using TCGA Infinium 450K data
Based on TCGA Infinium 450K data, for any DMR identi-
fied in our study that overlaped at least one Infinium
probe, we computed the average methylation level (aML)
in each cancer type group (described in Additional file 1:











where n is the number of samples in a specific cancer
type group, w is the number of available Infinium CpG
probes within the corresponding DMR, and BVij is beta-
value of the j th Infinium CpG probe within that DMR
in the i th sample.
DNA methylation change (DMC) were calculated as:
DMC ¼ aMLc−aMLn
where aMLc is the averaged methylation level of a
DMR in a specific cancer type group; aMLn is the aver-
aged methylation level of a DMR in the normal control
group.
Based on TCGA Infinium 450K data, all DMRs be-
longing to EC-shared DMRs,
EAC tpDMRs, and UPSC tpDMRs, were validated by
performing the Man-Whitney U test to examine the sig-
nificance of DNA methylation difference between cancer
group and normal controls. P-values were corrected for
multiple testing by the Benjamini-Hochberg method. Vali-
dated DMRs were defined by the criteria: 1) the DMR has
an adjusted p-value of < 0.05 between the cancer group
and normal controls; 2) the DMR has an averaged DNA
methylation change of over 0.05 in the cancer group com-
pared to normal controls; 3) the direction of DNA methy-
lation change between cancer and control samples in
TCGA Infinium 450K data must fit our predication.
Zhang et al. BMC Genomics 2014, 15:868 Page 17 of 21
http://www.biomedcentral.com/1471-2164/15/868ENCODE chromHMM chromatin state annotation
ChromHMM annotation of nine ENCODE cell lines [66]
were obtained from the UCSC Genome Browser [114]. The
nine cell lines are: H1 ESC, GM12878, K562, HepG2,
HUVEC, HMEC, HSMM, NHEK, and NHLF. The genome
was split to 500 bp windows. For each 500 bp window, we
assigned overlapping annotations of “promoter”, “enhancer”,
and “insulator” states from these chromHMM maps. In
each cell line, the state of each 500 bp window was assigned
to the dominant chromHMM state, defined as the state that
occupied over 50% of a given window. After merging the
data from 9 cell lines, “promoter” regions were defined as
the windows have a dominant “promoter” chromHMM
state in at least one cell line. “Enhancer” regions were de-
fined as windows have a dominant “enhancer” chromHMM
state in at least one cell line but no “promoter” chromHMM
state in any cell line.ENCODE TFBS and DHS data
ENCODE TFBS data and Dnase I Hypersensitive sites
(DHS) data were downloaded from the UCSC Genome
Browser ENCODE data portal [114]. TFBS data con-
tained 4,380,444 regions; DHS data contained 1,281,988
regions.Enrichment calculation
The binding site enrichment score (ES) for each genomic
feature, DHS, and transcription factor with respect to
DMRs was calculated as:
ES ¼ n–hit=n–DMR
N–hit=N–all
Where n _ hit is the number of DMRs that contain
specific a genomic feature, experimentally annotated
DHS, or TFBS; n _DMR is the total number of DMRs;
N _ hit is the number of genomic windows with a spe-
cific genomic feature, annotated DHS, or TFBS; N _ all
is the number of 500 bp windows in the human genome
(hg19).Gene ontology enrichment analysis
Gene Ontology (GO) analyses for biological processes
were performed using the GREAT package [115]. Gene
regulatory domains were defined by default as regions
spanning 5 kb upstream to 1 kb downstream of the TSS
(regardless of other nearby genes). Gene regulatory
domains were extended in both directions to the nearest
gene's basal domain but no more than a maximum
extension in one direction. Only categories that were
below a false discovery rate of 0.05 were reported.Reporter gene assay
Candidate transposable element sequences were ampli-
fied from genomic DNA using Pfu-polymerase (Agilent)
and primers containing KpnI- or BglII- restriction sites.
PCR products were gel-purified using the Qiagen Gel
purification kit and then digested by the corresponding
restriction enzymes (NEB). The digested PCR products
were cloned into the pGL4.23[luc2/minP]-vector (Promega,
E8411) using T4-ligase (NEB) and transformed into chem-
ically competent DH5α-cells. The positive clones were
verified by enzyme digestion and sequencing. 800 ng of
reporter plasmid (or empty pGL4.23[luc2/minP]-vector
control) was cotransfected into HEK-293T cell line with the
CMV promoter driven Renilla luciferase plasmid (200 ng).
The luciferase activity was measured 48 hours post trans-
fection and normalized by the relative Renilla control.
Genomic locations of candidates and primer information
were summarized in Additional file 1: Table S9.
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